Table 1. Patients' characteristics

	No. of patients
M/F	10/16*
Median age (yr)	62 (35–87)
Median Karnofsky performance status (%)	70 (40–90)
Measurable or assessable disease	19
Sites of involvement	
Single	7
Multiple	19
Liver	15
Previous treatment	
Palliative bypass surgery	16
Chemotherapy	6†
5-FU/radiotherapy	3

*4 premenopausal, 12 postmenopausal.
†5-fluorouracil (5FU) alone or in combination.

With confirmation of tissue diagnosis and known unresectable tumour as documented by laparotomy or radiological investigation, treatment was started with tamoxifen 20 mg orally twice daily. Patients were followed up every 2–3 months until death. Although desirable, measurable or assessable disease was not required in this trial. The endpoint of evaluation was survival from time of diagnosis. Oestrogen receptor status was not assessed in the pancreatic tumour specimens.

Among the 19 patients with assessable or measurable disease, none had objective tumour response. All patients have died at the time of analysis. Survival did not vary significantly by sex. Median survival for women and men was 4.6 and 4.1 months, respectively. The median survival for the entire group of 26 patients was 4.4 months. There was no toxicity associated with tamoxifen administration.

The lack of objective tumour response in the patients with evaluable disease and the median overall survival were similar to the natural history of untreated metastatic pancreatic cancer. Those results were not only disappointing, but also contrasted with the results of other studies that used the same dose and schedule of tamoxifen [5, 6]. In addition we found no survival benefit for postmenopausal patients as described by Wong *et al.* [7].

In a small study there is the risk of accruing, by design or chance, a skewed population that may have a preponderance of good or poor prognostic factors. Several adverse prognostic factors in our patients, such as poor performance status and a high proportion with liver metastases, might have influenced our results. However, apart from the few other negative reports on the efficacy of tamoxifen in pancreatic cancer [8], the outcome of controlled studies started in Stockholm, Norway and the U.K. in mid-1987 [9], has not been reported. Hormonal treatment of advanced pancreatic cancer might appear attractive due to the ineffectiveness of conventional chemotherapy, the excellent tolerance and low costs of oral anti-oestrogens, and the encouraging preliminary clinical studies. However, we believe that such treatment cannot be recommended unless its effectiveness is proven convincingly in prospective randomized trials. Hormonal manipulation with certain other drugs such as high-dose megestrol acetate, aimed at producing subjective improvement and at increasing appetite and weight [10], could be considered in pancreatic cancer.

1. Greenway BA, Iqbal MJ, Johnson PJ, Williams R. Oestrogen receptor proteins in malignant and fetal pancreas. *Br Med J* 1981, **283**, 751–753.
2. Satake K, Yoshimoto T, Mukai R, Umeyama K. Estrogen receptors in 7,12-dimethylbenzanthracene (DMBA) induced pancreatic carcinoma in rats and in human pancreatic carcinoma. *Clin Oncol* 1982, **8**, 49–54.
3. Andren-Sandberg A. Progress in estrogen receptors and estrogen-binding proteins in pancreatic cancer. *Organ Syst N Lett* 1986, **2**, No. 3.
4. Greenway BA, Duke D, Pym B, Iqbal MJ, Johnson PJ, Williams R. The control of human pancreatic adenocarcinoma xenografts in nude mice by hormone therapy. *Br J Surg* 1982, **69**, 595–597.
5. Tonnesen K, Kamp-Jensen M. Antioestrogen therapy in pancreatic carcinoma: a preliminary report. *Eur J Surg Oncol* 1986, **12**, 69–70.
6. Theve NO, Pousette A, Carlstroem K. Adenocarcinoma of the pancreas—a hormone sensitive tumor? A preliminary report on Nolvadex treatment. *Clin Oncol* 1983, **9**, 193–197.
7. Wong A, Chan A, Keith A. Tamoxifen therapy in unresectable adenocarcinoma of the pancreas. *Cancer Treat Rep* 1987, **71**, 749–750.
8. Crowson MC, Dorell A, Rolfe EB, Fielding JWL. A phase II study to evaluate tamoxifen in pancreatic adenocarcinoma. *Eur J Surg Oncol* 1986, **12**, 335–336.
9. Greenway BA. Carcinoma of the exocrine pancreas: a sex hormone responsive tumor? *Br J Surg* 1987, **74**, 441–442.
10. Aisner J, Tchekmedyian S *et al.* Studies of high-dose megestrol acetate: potential applications in cachexia. *Semin Oncol* 1988, **15**, 68–75 (Suppl. 1).

Eur J Cancer, Vol. 26, No. 7, pp. 852–853, 1990.
Printed in Great Britain
0277-5379/90$3.00 + 0.00

Cancer Cells in Effusions and Increases in T-Activated Lymphocytes

Massimo Geuna, Alessandra Linari and Gianni Bussolati

EFFUSIONS CONTAINING cancer cells model immune reactivity to cancer since, reflecting the tumour and host immune relations, they may represent what is occurring in solid tumours. 49 effusions from patients with or without cancer were investigated with markers of lymphocyte subsets and activation.

Effusions arriving at our laboratory for cytological examination were selected when the cell count was over 3–5 × 10^5/ml. 24 effusions contained cancer cells (breast 12, lung 6, ovary 4, bladder 1, and pancreatic 1). 5 other patients had cancer but their effusions were free of cancer cells. 20 cases were reactive effusions from patients with either cirrhosis or pleuritis. 1 patient had B chronic lymphocytic leukaemia. Cancer cells were identified cytologically and by staining with HMFG2 antibody and immunoperoxidase [1, 2]. 1–5 × 10^5 cells were tested with monoclonal antibodies [3] against T cells and subsets (Leu

Correspondence to G. Bussolati.
Massimo Geuna, Alessandra Linari and Gianni Bussolati are at the Department of Biomedical Sciences and Human Oncology, University of Turin, Via Santena 7, 10126 Torino, Italy.